BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology. The...
BioCentury | Oct 27, 2020
Distillery Therapeutics

FAP inhibition for the treatment of osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis The endogenous bone growth factor CLEC11A and other inhibitors of FAP could treat osteoporosis. In cultures of mouse primary bone marrow cells, a tool compound FAP inhibitor reduced osteoclast differentiation. In...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
BioCentury | May 26, 2020
Distillery Therapeutics

Boosting Tnip3-mediated inhibition of MAP3K7 for non-alcoholic steatohepatitis

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Promoting the expression of Tnip3, which inhibits inflammation, and its prevention of MAP3K7 activation could treat NASH. Hepatic levels of Tnip3 protein and mRNA were lower in NASH...
BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

Human B and T cell responses to the novel coronavirus provide natural biomarkers and blueprints for COVID-19 countermeasures. Virtual presentations hosted Thursday by BioCentury and Repertoire Immune Medicines Inc. showcased emerging work on SARS-CoV-2 antigens...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

Rgenta launched this month with a $20 million seed round to develop compounds that enhance regulatory RNA-protein interactions. The company is disease-agnostic and using amenability to small molecule intervention to guide target selection. Co-founder, President...
BioCentury | Apr 9, 2020
Tools & Techniques

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

Deploying its HPV serology testing lab to validate COVID-19 assays is one of three ways NIH’s National Cancer Institute is retooling cancer research activities to take on the pandemic. In a virtual advisory committee meeting...
BioCentury | Mar 31, 2020
Deals

Brii Bio, Tsinghua, Third People’s Hospital to develop COVID-19 patient-derived neutralizing antibodies

Taking advantage of access to hospitals that have treated some of the earliest COVID-19 patients, Brii Bio has partnered with Tsinghua University and Third People’s Hospital of Shenzhen to discover and develop COVID-19 mAbs derived...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
Items per page:
1 - 10 of 1656
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology. The...
BioCentury | Oct 27, 2020
Distillery Therapeutics

FAP inhibition for the treatment of osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis The endogenous bone growth factor CLEC11A and other inhibitors of FAP could treat osteoporosis. In cultures of mouse primary bone marrow cells, a tool compound FAP inhibitor reduced osteoclast differentiation. In...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
BioCentury | May 26, 2020
Distillery Therapeutics

Boosting Tnip3-mediated inhibition of MAP3K7 for non-alcoholic steatohepatitis

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Promoting the expression of Tnip3, which inhibits inflammation, and its prevention of MAP3K7 activation could treat NASH. Hepatic levels of Tnip3 protein and mRNA were lower in NASH...
BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

Human B and T cell responses to the novel coronavirus provide natural biomarkers and blueprints for COVID-19 countermeasures. Virtual presentations hosted Thursday by BioCentury and Repertoire Immune Medicines Inc. showcased emerging work on SARS-CoV-2 antigens...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

Rgenta launched this month with a $20 million seed round to develop compounds that enhance regulatory RNA-protein interactions. The company is disease-agnostic and using amenability to small molecule intervention to guide target selection. Co-founder, President...
BioCentury | Apr 9, 2020
Tools & Techniques

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

Deploying its HPV serology testing lab to validate COVID-19 assays is one of three ways NIH’s National Cancer Institute is retooling cancer research activities to take on the pandemic. In a virtual advisory committee meeting...
BioCentury | Mar 31, 2020
Deals

Brii Bio, Tsinghua, Third People’s Hospital to develop COVID-19 patient-derived neutralizing antibodies

Taking advantage of access to hospitals that have treated some of the earliest COVID-19 patients, Brii Bio has partnered with Tsinghua University and Third People’s Hospital of Shenzhen to discover and develop COVID-19 mAbs derived...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
Items per page:
1 - 10 of 1656